Challenger Limited told the ASX it had received a non-binding, conditional indicative offer from TAL Daiichi Life Australia, a Daiichi Life Group subsidiary, for the remaining 79.5% of its shares. The proposed price is A$11.80 a share. Bloomberg flagged the move on 18 October; the exchange notice is dated 19 October. It is not a closed deal. It is not investment advice.

The bid would go by scheme of arrangement, with due diligence, a scheme implementation agreement, regulatory approvals and a board recommendation. Challenger notes a 17.7% premium to the one-month volume-weighted average of A$10.03. Shareholders, the company said, need take no action now. There is no certainty of a binding offer.

Headlines spoke of about US$4.4 billion. The ASX maths is different: A$11.80 on the remaining stock, or, in market readings, about A$6.3 billion for the 79.5% stake and about A$7.9 billion for the whole of Challenger. We keep the notice figures, not the headline ones.

Challenger, listed in Sydney, presents itself as an asset manager and as Australia’s large annuity provider. Daiichi Life is a Japanese insurer with Asia-Pacific operations. Challenger’s board is considering the approach. Until a signed agreement, the share can move on expectation, not on an outcome.

The conditions include approvals. A refusal, failed diligence or a renegotiated price would close the path. A scheme usually needs shareholder votes and an Australian court. None of that has happened.

Anyone who already holds Challenger stock has, from this notice, no duty to sell. Anyone who does not hold it has no reason to buy. This is a market step, not a takeover done.

Image: Chris Olszewski, Sydney CBD skyline, 2023, CC BY-SA 4.0, Wikimedia Commons; the city, not a Challenger board meeting in October 2026.

Sources consulted: Daiichi Life Offers to Buy Remainder of Australia Challenger - Bloomberg; Indicative non-binding offer received - Challenger Limited, ASX.